News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Concert Pharmaceuticals, Inc. Presents Findings Demonstrating Enhanced Potency of CTP-221, a Deuterated S-Enantiomer of Lenalidomide


12/10/2012 10:02:19 AM

ATLANTA--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced it presented preclinical results demonstrating that CTP-221, Concert’s deuterated S-lenalidomide analog, exhibits enhanced potency compared to racemic lenalidomide. Revlimid®, which is marketed for the treatment of multiple myeloma and del(5q) myelodysplastic syndromes, contains racemic lenalidomide as its active pharmaceutical ingredient. The CTP-221 findings were presented in a poster at the American Society of Hematology’s (ASH) 2012 Annual Meeting. Concert expects to complete preclinical testing of CTP-221 and file an Investigational New Drug Application in 2013.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES